JPRN-UMIN000051087招募中2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinoma - GIANT2 Trial
Kansai Clinical Oncology Group(KCOG)0 个研究点目标入组 28 人开始时间: 2024年4月1日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients with contraindications to Gemcitabine, Cisplatin or Bevacizumab 2)Patients with uncontrolled heart disease, renal disease, or diabetes 3) Patients with interstitial pneumonia or pulmonary fibrosis (confirmed by CT examination) 4)Patients with intestinal paralysis or intestinal obstruction 5) Patients with infectious diseases requiring treatment 6)Patients who have received radiotherapy to the chest or abdomen 7) Patients with active double cancer (not including carcinoma in situ) 8)Patients with a history of severe drug hypersensitivity 9) Patients with a history of underlying disease associated with obstructive bowel disease including subileus, patients with diverticulum, intestinal fistula, gastrointestinal perforation, intra-abdominal abscess, obvious rectosigmoid colon invasion by pelvic examination, CT examination Patients with clinical symptoms of obvious intestinal infiltration or intestinal obstruction due to 10)Patients with symptomatic central nervous system metastases 11)Patients who are pregnant or breastfeeding, or who may become pregnant during the treatment period of this protocol and are not willing to use contraception 12)Patients with the following diseases 13)Patients who are currently or recently (within 30 days prior to the start of this protocol treatment) receiving or receiving other investigational drugs (including unapproved drugs). 14)Patients who are judged inappropriate for participation in this study by investigators or subinvestigators
研究者
相似试验
进行中（未招募）
1 期
ew treatment option for refractory testicular cancer.Refractory histologically confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma germ cell tumoursEUCTR2016-000171-24-SKárodný onkologický ústav43
招募中
2 期
Biliary tract cancer cross-over studybiliary tract cancerJPRN-jRCT1041230014Yamashita Tatsuya50
已完成
1 期
Phase I study of Gemcitabine, Cisplatin and S-1 for advanced biliary tract cancer.Biliary tract cancerJPRN-UMIN000006123Tsukuba University Hospital, Division of Gastroenterology12
招募中
2 期
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphomarelapsed or refractory non-Hodgkin's lymphomaJPRN-UMIN000015998Gifu University Hospital20
尚未招募
不适用
Phase I study of gemcitabine and carboplatin plus sorafenib in patients with advanced solid tumorsadvanced solid tumors10027655CancerNL-OMON31053Antoni van Leeuwenhoek Ziekenhuis28